Gilead Sciences, Inc. (NASDAQ: GILD) – Recent News Summary
Positive Sentiment:
Cantor Fitzgerald raised its FY2025 EPS estimate from $7.96 to $8.05, maintained an Overweight rating, and set a $125 price target.
Cantor Fitzgerald Forecasts Gilead Sciences FY2025 Earnings
Positive Sentiment:
Gilead and the Global Fund finalized a deal to supply the long-acting HIV prevention drug lenacapavir to low-income countries, expanding global access and supporting future revenue growth.
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries
Positive Sentiment:
Arcus Biosciences announced that the Gilead-partnered cancer drug has received FDA orphan drug status, potentially enhancing market exclusivity and future sales prospects.
Arcus says Gilead-partnered cancer drug won FDA orphan status
Positive Sentiment:
A bullish analysis on Dividend Talks highlighted factors supporting Gilead’s growth potential, including attractive valuation metrics (23.3 trailing P/E, 14.0 forward P/E) and a diversified pipeline.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
Neutral Sentiment:
Reported short interest ticked up in July, but days-to-cover remains at 0.0 due to reporting quirks, indicating no material shift in bearish positioning.
Neutral Sentiment:
Zacks highlighted Gilead as both a strong momentum and a top value stock, reflecting mixed analyst views on its risk-reward profile.
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Neutral Sentiment:
Recent broker commentary offers varied analyst ratings, advising investors to reassess Gilead’s risk-reward before making new commitments.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
Negative Sentiment:
The AIDS Healthcare Foundation criticized Gilead for excluding Latin America and the Caribbean from its lenacapavir procurement deal, raising reputational and access concerns.
AHF: Gilead's Greed Costs Latin America HIV Protection
Posted 7h ago
AI Generated. May Contain Errors.